Mode
Text Size
Log in / Sign up

FABP2 serves as a sensitive biomarker of intestinal mucosal injury in inflammatory bowel diseaseFABP2 Protein May Help Identify Inflammatory Bowel Disease Damage

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Recognize FABP2 as a sensitive biomarker for intestinal mucosal injury in patients with inflammatory bowel disease.

This systematic review synthesizes evidence regarding fatty acid-binding protein 2 (FABP2) in the context of inflammatory bowel disease. The scope includes its role as a diagnostic biomarker and its potential involvement in the underlying pathophysiology of the condition.

The synthesis indicates that FABP2 is a sensitive biomarker for intestinal mucosal injury. Furthermore, it may contribute to the pathogenesis and progression of inflammatory bowel disease, potentially through the modulation of the PPARγ signaling pathway. These mechanisms may involve lipid metabolism, gut microbiota-host interactions, and the attenuation of intestinal inflammation.

Authors note that precise assessment of disease activity remains a challenge for clinicians. Additionally, the development of safe and effective targeted therapeutics based on these pathways faces significant hurdles. While FABP2 is well-supported as a diagnostic biomarker, its potential as a therapeutic target requires further investigation to overcome current limitations in clinical translation.

How this fits prior evidence

This systematic review addresses a gap in understanding molecular biomarkers for inflammatory bowel disease. While prior evidence confirms that patients with inflammatory bowel disease are at increased risk of MACE and all-cause mortality, this finding focuses on the role of FABP2 as a sensitive biomarker for mucosal injury and its potential involvement in pathogenesis.

Researchers have identified a protein called Fatty acid-binding protein 2 (FABP2) that may serve as an important tool for medical diagnosis. This review of existing evidence suggests that FABP2 is a sensitive biomarker for detecting injury to the intestinal lining.

In addition to being a marker, researchers believe this protein might play a role in how inflammatory bowel disease develops and progresses. It may influence specific pathways related to lipid metabolism and gut health. Because it interacts with these systems, it could eventually help doctors understand how inflammation is managed in the body.

While the findings are promising for diagnosis, there are still hurdles to overcome. It is currently difficult to measure exact disease activity accurately. Developing new treatments based on this protein also faces several challenges. More research is needed to confirm exactly how these processes work before they can change standard medical care.

What this means for you:
FABP2 is a promising marker for intestinal damage in inflammatory bowel disease, but more research is needed.

Common questions

What is the role of FABP2 in inflammatory bowel disease?

FABP2 may contribute to how inflammatory bowel disease develops and progresses. It is thought to potentially influence the progression of the condition by modulating specific signaling pathways. While it shows promise as a marker for intestinal damage, more research is needed to fully understand its role.

Can FABP2 be used to diagnose intestinal damage?

Yes, evidence supports FABP2 as a sensitive biomarker for identifying injury to the intestinal mucosa. This means it could help doctors detect physical damage to the gut lining in patients with inflammatory bowel disease.

Is there a new treatment based on FABP2?

While FABP2 is well-supported as a diagnostic marker, its use as a target for new therapies is still being explored. Developing safe and effective treatments based on this protein currently faces several challenges and requires further investigation.

Study Details

Study typeSystematic review
EvidenceLevel 1
PublishedAug 2026
View Original Abstract ↓
Fatty acid-binding protein 2 (FABP2) is an intestine-specific cytoplasmic lipid chaperone with a molecular weight of approximately 14–15 kDa that plays a pivotal role in the uptake, intracellular trafficking, and metabolism of long-chain fatty acids. Emerging evidence indicates that FABP2 is not only a sensitive biomarker of intestinal mucosal injury but also may contribute to the pathogenesis and progression of IBD, potentially through the modulation of PPARγ signaling pathway, although the underlying mechanisms require further investigation. This review systematically summarizes the structural and functional characteristics of the fatty acid-binding protein (FABP) family members, with particular emphasis on the biological features of FABP2. We discuss the involvement of FABP2 in multisystem diseases and highlight its specific relevance in IBD. Furthermore, we summarize current evidence regarding the potential molecular mechanisms by which FABP2 may influence IBD, including its possible roles in intestinal barrier dysfunction, lipid metabolism, gut microbiota-host interactions, and its potential contribution to the attenuation of intestinal inflammation, possibly through regulation proliferation and differentiation of intestinal stem cells. Although the biological investigations of FABP2 in inflammatory bowel disease (IBD) have yielded promising findings, its clinical translation is still confronted with challenges such as the precise assessment of disease activity and the development of safe and effective targeted therapeutics. Collectively, this review provides a comprehensive reference for researchers and clinicians in the IBD field, highlighting the well-supported role of FABP2 as a diagnostic biomarker while discussing its potential as a therapeutic target, an area that warrants further mechanistic and clinical investigation.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.